research Prevalence of the metabolic syndrome in African populations: A systematic review and meta-analysis
Metabolic syndrome is common in African populations, needing urgent prevention and treatment.
Search
for
Sort by
Research
930-960 / 1000+ resultsresearch Prevalence and Burden of Vitiligo in Africa, the Middle East and Latin America
Vitiligo causes significant emotional stress in Africa, the Middle East, and Latin America, with limited treatment options available.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Dermatologic Changes in Experimental Model of Long COVID
Mice with a virus similar to COVID-19 had skin damage, but a special treatment helped repair it.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences
Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
research Insights into Alopecia Areata: A Systematic Review of Prevalence, Pathogenesis, and Psychological Consequences
Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.
research Overview of alopecia areata for managed care and payer stakeholders in the United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research BENIGN PREMATURE ADRENARCHE: CLINICAL FEATURES AND SERUM STEROID LEVELS
Dexamethasone effectively normalizes elevated steroid levels in girls with premature adrenarche.
research Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
research What do we know about phytotherapy of benign prostatic hyperplasia?
Some plant-based treatments can help with benign prostatic hyperplasia symptoms, but more research is needed to confirm their safety and effectiveness.
research Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
Men with enlarged prostates often have more severe baldness.
research Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia
Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
research Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
Cinnamomi cortex may help treat prostate enlargement by reducing related proteins.
research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
research Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review
Men with BPH should discuss potential sexual side effects with doctors before treatment, as some treatments can affect ejaculation.
research Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
research Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
research Baldness, benign prostate hyperplasia, prostate cancer and androgen levels
The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
research Androgenetic alopecia as an early marker of benign prostatic hyperplasia
Early hair loss may indicate prostate issues.
research Risks and side effects in the medical management of benign prostatic hyperplasia
Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the Male
Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review
COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.